Bortezomib Maintenance in High Risk DLBCL

Summary

This study is an Open-labeled, multicenter Phase II study of Bortezomib for maintenance therapy in patients with high risk diffuse large B cell lymphoma (DLBCL). Primary objective is 3 years relapse free survival (RFS) and Secondary objectives are 3 years overall survival (OS), 3 years event free survival (EFS),Toxicities profiles, Quality of Life (FACT\&GOG-Ntx)

Timeline

Start

2015-04-08

Primary completion

2018-10-30

Completion

2021-10-30

Drugs

Indications